Clinical Trial

A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in Chinese males aged 18-45 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-07.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-07-28
Trial Details
NCT Number NCT06866574
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd
Conditions Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer, Genital Warts
Enrollment 9,300 participants
Start Date 2025-04-11
Primary Completion 2031-09-30 (estimated)
Study Completion 2031-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-31